摘要
目的 探讨不同药物组合治疗方案对幽门螺旋杆菌阳性的消化性溃疡与慢性胃炎所产生的经济效果。方法 运用药物经济学成本-效果分析法对幽门螺旋杆菌(Hp)感染的消化性溃疡和慢性胃炎的3种治疗方案进行分析评价。结果 3种方案的成本-效果比分别为14.52、13.62、12.24。无论是从成本-效果比分析(C/E),还是从增长的成本-效果比分析(ΔC/ΔE),均得出C方案为治疗Hp阳性的消化性溃疡的最佳方案。结论 药物经济学在优化治疗方案,指导合理用药,提高经济效益方面具有重要作用。
Objective To evaluate the economic effectiveness of different pharmacotherapeuticschemes for peptic ulcer and chronic gastritis with infection of Helicobacteria pylori(Hp).MethodsThree therapeutic schemes(including A,B and C schemes) for Hp infection were evaluated with pharmacoeconomiccost-effectiveness analysis. Results The cost-effectiveness ratios of three therapeutic schemes were14.52,13.62 and 12.24 individually;The results showed that C was the best scheme from either cost-effectiveness analysis(C/E) or increasing cost effectiveness analysis(ΔC/ΔE).ConclusionPharmacoeconomics is very important in optimizing therapeutic scheme, guiding rational drug use andincreasing economic effectiveness.
出处
《国际医药卫生导报》
2003年第18期28-29,共2页
International Medicine and Health Guidance News
关键词
幽门螺旋杆菌
治疗方案
药物经济学
成本-效果分析
Hp (helicobacteria pylori) Therapeutic scheme Pharmacoeconomics Cost-effectiveness analysis
